Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bristol-Myers Squibb CoXSWX:BMY 73 Shiller PE Ratio is 38.54 as of Sep. 03, 2026, which is 14% above its 10-year median of 33.66. GuruFocus rates XSWX:BMY with a GF Score™ of 73/100 and a GF Value™ of CHF45.75 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 526 Drug Manufacturers companies, Bristol-Myers Squibb Co ranks worse than 71.67% on this metric.
The historical rank and industry rank for Bristol-Myers Squibb Co's Shiller PE Ratio or its related term are showing as below:
XSWX:BMY'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.28 Med: 33.66 Max: 54.46
Current: 38.72
During the past years, Bristol-Myers Squibb Co's highest Shiller PE Ratio was 54.46. The lowest was 18.28. And the median was 33.66.
XSWX:BMY's Shiller PE Ratio is ranked worse than 71.67% of 526
companies
in the Drug Manufacturers industry
Industry Median: 25.32
vs XSWX:BMY: 38.72
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Bristol-Myers Squibb Co's adjusted earnings per share data for the three months ended in Jun. 2026 was CHF1.295. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is CHF1.41 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Bristol-Myers Squibb Co (XSWX:BMY) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Bristol-Myers Squibb Co Shiller PE Ratio Related Terms
Bristol-Myers Squibb Co Shiller PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BMY vs PFE, GILD, AMGN: Shiller PE Ratio Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co Shiller PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's Shiller PE Ratio falls into.
Bristol-Myers Squibb Co Shiller PE Ratio Calculation
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Bristol-Myers Squibb Co (XSWX:BMY) has a Shiller PE Ratio of 38.54 as of Sep. 03, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Bristol-Myers Squibb Co and its competitors. This is 14% above median its historical median of 33.66. Over the past decade, Bristol-Myers Squibb Co's Shiller PE Ratio has ranged from 18.28 to 54.46. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #377 out of 526 companies in the Drug Manufacturers industry, placing it in the top 71.7%.
Is Bristol-Myers Squibb Co's Shiller PE Ratio too high?
Bristol-Myers Squibb Co's current Shiller PE Ratio of 38.54 is 14% above median its 10-year median of 33.66. Over the past 10 years, this metric has ranged from a low of 18.28 to a high of 54.46. The Drug Manufacturers industry median Shiller PE Ratio is 25.32. Bristol-Myers Squibb Co's value of 38.54 is 52.2% above this industry median. Based on the distribution chart, Bristol-Myers Squibb Co ranks #377 out of 526 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bristol-Myers Squibb Co has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Shiller PE Ratio compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #377 out of 526 companies for Shiller PE Ratio. This places Bristol-Myers Squibb Co in the lower half of its industry. The industry median Shiller PE Ratio is 25.32. Bristol-Myers Squibb Co's value of 38.54 is 52.2% above this benchmark. Historically, Bristol-Myers Squibb Co's own Shiller PE Ratio has ranged from 18.28 to 54.46 over the past decade. While the company's 10-year median is 33.66 vs. the industry median of 25.32, Bristol-Myers Squibb Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Drug Manufacturers company?
The median Shiller PE Ratio among Drug Manufacturers companies is 25.32, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bristol-Myers Squibb Co's current Shiller PE Ratio of 38.54 is 52.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Bristol-Myers Squibb Co and its competitors. For the Drug Manufacturers industry, the median Shiller PE Ratio is 25.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bristol-Myers Squibb Co's current Shiller PE Ratio is 38.54, which is 14% above median its own 10-year median of 33.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (XSWX:BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF45.75, compared to a current price of CHF54.34 — trading 18.8% above its estimated fair value. The current Shiller PE Ratio is 38.54, which is 14% above median its 10-year median of 33.66 and 52.2% above the Drug Manufacturers industry median of 25.32. Bristol-Myers Squibb Co's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Bristol-Myers Squibb Co (XSWX:BMY), the current Shiller PE Ratio is 38.54 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (XSWX:BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of CHF54.34 is trading 18.8% above its estimated GF Value™ of CHF45.75.
GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.
Key valuation signals for XSWX:BMY:
Shiller PE Ratio: 38.54 (14% above median its 10-year median of 33.66)
GF Value™: CHF45.75 vs. price of CHF54.34 (18.8% above fair value)
Industry Position: 52.2% above the Drug Manufacturers median (#377 of 526)
No single metric tells the full story. See the XSWX:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
73GF Score
Get the complete analysis for XSWX:BMY
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BMY has been successfully added to your 
